Labetalol

Labetalol

SCHEMBL3499242

CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1.CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3

The experimentally established mechanism targets of Labetalol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB1 known ✓ P08588 13/20 1.00
ADRA1A known ✓ P35348 13/20 1.00
ADRB2 known ✓ P07550 13/20 1.00
ADRA1D known ✓ P25100 12/20 1.00
ADRA1B known ✓ P35368 12/20 1.00
ADRA2A known ✓ P08913 2/20 1.00
ADRB3 known ✓ P13945 11/20 0.98
ADRA2B known ✓ P18089 1/20 0.98
ADRA2C known ✓ P18825 1/20 0.98
CYP2D6 P10635 2/20 1.00
KDM4E B2RXH2 2/20 1.00
ALDH1A1 P00352 2/20 1.00
LMNA P02545 2/20 1.00
HPGD P15428 2/20 1.00
HSD17B10 Q99714 2/20 1.00
HTR1A P08908 2/20 1.00
SLC6A2 P23975 2/20 1.00
SLC6A4 P31645 2/20 1.00
OPRM1 P35372 1/20 1.00
DRD3 P35462 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Labetalol SCHEMBL29687428 1.00 ADRB1 (1.00) ADRB1ADRA1AADRB2ADRA1DADRA1B
Labetalol SCHEMBL7273474 1.00 ADRB1 (1.00) ADRB1ADRA1AADRB2ADRA1DADRA1B
Labetalol SCHEMBL4582 1.00 ADRB1 (1.00) ADRB1ADRA1AADRB2ADRA1DADRA1B
Labetalol SCHEMBL10356800 1.00 ADRB1 (1.00) ADRB1ADRA1AADRB2ADRA1DADRA1B
Labetalol SCHEMBL10882744 1.00 ADRB1 (1.00) ADRB1ADRA1AADRB2ADRA1DADRA1B
Labetalol SCHEMBL41231 1.00 ADRB1 (1.00) ADRB1ADRA1AADRB2ADRA1DADRA1B
Dilevalol SCHEMBL79468 1.00 ADRB1 (1.00) ADRB1ADRA1AADRB2ADRA1DADRA1B
Labetalol SCHEMBL41230 0.99 ADRB1 (1.00) ADRB1ADRA1AADRB2ADRA1DADRA1B
Labetalol SCHEMBL10450118 0.99 ADRB1 (1.00) ADRB1ADRA1AADRB2ADRA1DADRA1B
Labetalol SCHEMBL9614383 0.99 ADRB1 (1.00) ADRB1ADRA1AADRB2ADRA1DADRA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130295042-A1 Peptides and Peptide Mimetics to Treat Pathologies Associated With Eye Disease UAB RESEARCH FOUNDATION 2013-11-07 US disclosed
US-8568766-B2 Peptides and peptide mimetics to treat pathologies associated with eye disease THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2013-10-29 US disclosed
US-20100143444-A1 PEPTIDES AND PEPTIDE MIMETICS TO TREAT PATHOLOGIES ASSOCIATED WITH EYE DISEASE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2010-06-10 US disclosed
WO-2005099699-A1 COMBINATION OF (S)-AMLODIPINE AND A BETA-BLOCKER, AND METHODS FOR REDUCING HYPERTENSION SEPRACOR INC. (US) 2005-10-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100143444-A1 PEPTIDES AND PEPTIDE MIMETICS TO TREAT PATHOLOGIES ASSOCIATED WITH EYE DISEASE APOB, IAPP, APOL1 ADRB1 1257/4885ADRA1A 1559/4885ADRB2 2113/4885
US-20130295042-A1 Peptides and Peptide Mimetics to Treat Pathologies Associated With Eye Disease APOB, IAPP, APOL1 ADRB1 1257/4885ADRA1A 1559/4885ADRB2 2113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.